We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

107 hedge funds and large institutions have $204M invested in Aratana Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less funds holding

Funds holding: 128107 (-21)

18% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 40

23% less capital invested

Capital invested by funds: $265M → $204M (-$60.4M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

63% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 30

97% less call options, than puts

Call options by funds: $4K | Put options by funds: $134K

Holders
107
Holders Change
-21
Holders Change %
-16.41%
% of All Funds
2.67%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
11
Increased
33
Reduced
40
Closed
30
Calls
$4K
Puts
$134K
Net Calls
-$130K
Net Calls Change
-$90K
Name Holding Trade Value Shares
Change
Change in
Stake
ARTA
76
A.R.T. Advisors
New York
$128K +$23.4K +2,900 +19%
GLRA
77
Gerald L. Ray & Associates
Texas
$124K +$8.09K +1,000 +6%
VOYA Investment Management
78
VOYA Investment Management
Georgia
$114K
State Board of Administration of Florida Retirement System
79
State Board of Administration of Florida Retirement System
Florida
$113K
SG Americas Securities
80
SG Americas Securities
New York
$113K +$127K +15,695 New
Bank of Montreal
81
Bank of Montreal
Ontario, Canada
$107K -$133K -16,453 -52%
AIM
82
Acrospire Investment Management
Illinois
$97K -$8.94K -1,105 -8%
Tudor Investment Corp
83
Tudor Investment Corp
Connecticut
$93K -$152K -18,749 -59%
RJFSA
84
Raymond James Financial Services Advisors
Florida
$92K
T. Rowe Price Associates
85
T. Rowe Price Associates
Maryland
$75K
Legal & General Group
86
Legal & General Group
United Kingdom
$72K +$36.7K +4,543 +84%
Bank of America
87
Bank of America
North Carolina
$60K +$12.3K +1,518 +22%
UBS Group
88
UBS Group
Switzerland
$52K -$10.2K -1,267 -15%
TRCT
89
Tower Research Capital (TRC)
New York
$33K +$37.2K +4,598 New
BlackRock
90
BlackRock
New York
$23K -$4.51K -558 -15%
UBS AM
91
UBS AM
Illinois
$15K +$16.8K +2,079 New
LTFS
92
Ladenburg Thalmann Financial Services
Florida
$14K
PA
93
Parallel Advisors
California
$14K +$16.2K +2,000 New
BNP Paribas Financial Markets
94
BNP Paribas Financial Markets
France
$12.8K -$5.56K -688 -28%
PNC Financial Services Group
95
PNC Financial Services Group
Pennsylvania
$11K
Barclays
96
Barclays
United Kingdom
$9K -$12.9K -1,591 -56%
MFW
97
Mosaic Family Wealth
Missouri
$7K
NSIM
98
North Star Investment Management
Illinois
$7K +$8.09K +1,000 New
MAM
99
Meeder Asset Management
Ohio
$6K +$7.06K +873 New
Royal Bank of Canada
100
Royal Bank of Canada
Ontario, Canada
$5K +$5.84K +722 +3,008%

PETX Hedge Fund Activity: Q4 2016 in Review

107 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2016, worth a combined $204M — down 23% from $265M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PETX and 11 opened new positions — a net loss of 19 holders — while 40 trimmed existing stakes and 33 added.

The largest buyer was Janus Henderson Investors US, adding an estimated $6.51M. The largest seller was Acadian Asset Management, cutting an estimated $5.67M.

  • 107 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2016, down from 128 in Q3 2016.
  • Funds reported $204M of Aratana Therapeutics, Inc. stock for Q4 2016, down 23% quarter-over-quarter.
  • 11 funds opened new Aratana Therapeutics, Inc. positions in Q4 2016 and 30 closed out, a net change of -19 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q4 2016 was Janus Henderson Investors US, an estimated $6.51M added.
  • The largest Aratana Therapeutics, Inc. seller in Q4 2016 was Acadian Asset Management, an estimated $5.67M sold.

Based on aggregated 13F filings for Q4 2016.